Originally published as JCO Early Release 10.1200/JCO.2005.11.148 on November 30 2004
Journal of Clinical Oncology, Vol 23, No 3 (January 20), 2005: pp. 441-447
© 2005 American Society of Clinical Oncology.
Long-Term Survival Rates of Patients With Prostate Cancer in the Prostate-Specific Antigen Screening Era: Population-Based Estimates for the Year 2000 by Period Analysis
Hermann Brenner,
Volker Arndt
From the German Centre for Research on Ageing, Heidelberg, Germany
Address reprint requests Hermann Brenner, M.D, MPH, Department of Epidemiology, German Centre for Research on Ageing, Bergheimer Str 20, D-69115 Heidelberg, Germany; e-mail: brenner{at}dzfa.uni-heidelberg.de
PURPOSE: In the era of widespread prostate specific antigen (PSA) screening, a large proportion of older men have to live with a diagnosis of prostate cancer. In this study, we applied a new method for up-to-date analysis of long-term survival to evaluate if and to what extent these patients still have any excess mortality compared to the general population.
METHODS: Five- and 10-year absolute and relative survival rates for the year 2000 were derived from the 1973 to 2000 database of the Surveillance, Epidemiology and End Results Program using the recently introduced period analysis methodology.
RESULTS: Overall, 5- and 10-year relative survival rates were approximately 99% and 95%; that is, excess mortality compared with the general population was as low as 1% and 5% within 5 and 10 years following diagnosis, respectively. Two-thirds of patients were diagnosed with well or moderately differentiated localized/regional prostate cancer, and among these patients, 5- and 10-year relative survival rates were above 100% (indicating the lack of any excess mortality) at all ages.
CONCLUSION: While the value of PSA screening for lowering mortality due to prostate cancer remains to be shown by randomized clinical trials, the majority of patients diagnosed with prostate cancer in the PSA screening era do not have excess mortality compared to the general population under current patterns of medical care. This information may be important for both clinical management of, and for patients' coping with, the disease.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
Related Editorial
- Period Analysis of Prostate Cancer Survival
George Wilding and Patrick Remington
JCO 2005 23: 407-409
[Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
B. A. Rybicki, C. Neslund-Dudas, C. H. Bock, A. Rundle, A. T. Savera, J. J. Yang, N. L. Nock, and D. Tang
Polycyclic Aromatic Hydrocarbon-DNA Adducts in Prostate and Biochemical Recurrence after Prostatectomy
Clin. Cancer Res.,
February 1, 2008;
14(3):
750 - 757.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Brenner, A. Gondos, and V. Arndt
Recent Major Progress in Long-Term Cancer Patient Survival Disclosed by Modeled Period Analysis
J. Clin. Oncol.,
August 1, 2007;
25(22):
3274 - 3280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Severi, H. A. Morris, R. J. MacInnis, D. R. English, W. Tilley, J. L. Hopper, P. Boyle, and G. G. Giles
Circulating Steroid Hormones and the Risk of Prostate Cancer
Cancer Epidemiol. Biomarkers Prev.,
January 1, 2006;
15(1):
86 - 91.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Brenner and V. Arndt
Further Enhanced Monitoring of Cancer Patient Survival by Stage-Adjusted Period Analysis
Cancer Epidemiol. Biomarkers Prev.,
August 1, 2005;
14(8):
1917 - 1921.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Wilding and P. Remington
Period Analysis of Prostate Cancer Survival
J. Clin. Oncol.,
January 20, 2005;
23(3):
407 - 409.
[Full Text]
[PDF]
|
 |
|
|